Category: ACN Newswire

HONG KONG, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.This collaboration strengthens the Company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.“This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest’s cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel’s development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients.”"As our novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel’s global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large."As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.Of note, the addition of Sumecigrel further enriches Everest Medicines’ cardiovascular portfolio. As the Company continues to expand its presence in the CKM (cardiovascular, kidney and metabolic) disease space, Sumecigrel is expected to strengthen its cardiovascular product portfolio and generate synergies with existing products and pipeline assets, further deepening the Company’s presence in related therapeutic areas.From a strategic perspective, this collaboration represents another important step in Everest Medicines’ ongoing efforts to deepen its presence across the Asia-Pacific region. Notably, the Company has continued to advance strategic partnerships and resource integration across the region. Through its collaboration with Mabworks, Everest secured the commercialization rights to Bejescin®, a third-generation anti-CD20 therapy, in multiple Asia-Pacific markets, further strengthening its portfolio in nephrology and autoimmune diseases. Industry observers believe that the licensing of Sumecigrel reflects Everest Medicines’ continued commitment to the Asia-Pacific market and its strategy of accelerating the regional development and commercialization of innovative therapies. As its regional product portfolio and operating capabilities continue to expand, Everest Medicines is well positioned to further leverage its integrated biopharmaceutical platform and accelerate the value realization of innovative therapies across the Asia-Pacific region. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHANGHAI, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator (GKA), at the 86th Scientific Sessions of the American Diabetes Association (ADA). Through oral and poster presentations that demonstrated the breadth and depth of its science, the Company showcased data from its Metabolic Homeostasis Technology Platform, spanning combination therapies, large-scale real-world outcomes, AI-powered precision medicine, and personalized care tools.Collectively, the presentations continued to demonstrate the significance of dorzagliatin’s mechanism of action – restoring glucose homeostasis at its root cause – and its therapeutic potential across a spectrum of complex metabolic diseases including Type 2 diabetes (T2D), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), obesity, and Maturity-Onset Diabetes of the Young Type 2 (MODY2).The new research findings strengthen Hua Medicine’s position as a global leader in glucose homeostasis research.I. Leveraging Metabolic Homeostasis Platform to Expand Therapeutic Landscape for Metabolic DiseasesDorzagliatin targets glucokinase (GK), the body’s fundamental glucose sensor, by repairing impaired GK function and expression in patients with Type 2 diabetes to enhance glucose sensitivity. Through coordinated multi-organ regulation across the pancreas, liver, and intestines, dorzagliatin fundamentally restores glucose homeostasis and addresses a broad spectrum of metabolic disorders.Building on this unique mechanism, Hua Medicine presented three combination therapy studies in animal models of metabolic disorder at ADA 2026. The data demonstrate that dorzagliatin acts synergistically with oral small molecule GLP-1 receptor agonists, THR-β agonists, and pan-PPAR agonists. It delivers benefits well beyond glycemic control, including weight reduction, lipid modulation, uric acid reduction, and improved insulin sensitivity.In an oral presentation, Hua Medicine reported preclinical findings evaluating dorzagliatin in combination with the oral small molecule GLP-1 receptor agonist orforglipron. In a significant scientific first, this study demonstrated synergies between a GKA and a small molecule GLP-1RA in animal models, providing a mechanistic and clinical rationale for an oral combination regime that pairs homeostasis restoration with incretin activation. Taken together, the dose-sparing effect, where low-dose combinations achieved comparable efficacy to high-dose monotherapy, addresses one of the most common barriers to GLP-1RA adherence in clinical practice: gastrointestinal tolerability.The study used diet-induced obese (DIO) human GLP-1R transgenic mice, which recapitulate human obesity-associated Type 2 diabetes. The 4-week once-daily oral treatment systematically evaluated monotherapy and combination therapy across key efficacy and safety parameters, including glycemic control, insulin secretion, body weight and lipid profiles.In this model, dorzagliatin repairs GK function across the pancreas, liver, and intestines to restore glucose homeostasis, enhance glucose-stimulated insulin secretion (GSIS), and promote endogenous GLP-1 secretion.Orforglipron directly activates GLP-1 receptors to induce robust weight loss, glycemic control, and lipid improvement; although it also carries the risk of adverse gastrointestinal (GI) events.Synergistic Glycemic Control: Combination therapy produced superior glucose-lowering effects versus monotherapy and enabled dose sparing potential, with low-dose combinations achieving efficacy comparable to high-dose monotherapy. Orforglipron amplified dorzagliatin-mediated improvements in β-cell function and hepatic glucose metabolism.Enhanced β-Cell Function: Dorzagliatin improves the β-cell function of DIO mice, and combined treatment synergistically boosted insulin secretion and sensitivity for better glycemic control and β-cell protection.Preserved Weight and Lipid Benefits: The combination fully retained orforglipron-induced weight reduction and lipid-lowering effects.Favorable Safety and Tolerability: The combination was well tolerated with no new safety signals. Dose sparing markedly reduced common GLP-1RA-related GI side effects such as nausea and vomiting, improving long-term adherence.Together, these complementary mechanisms across glycemic control, weight loss, and lipid improvement, position the potential combination as a highly effective, well-tolerated, and differentiated oral option for T2D patients with obesity. Hua Medicine plans to advance clinical studies to evaluate efficacy, safety, optimal dosing, and target patient populations most likely to benefit.Hua Medicine also presented the findings of two additional combination therapy studies in poster presentations:1.Dorzagliatin + Resmetirom (THR-β Agonist): In DIO mice with MASLD, the combination synergistically improved systemic metabolism and exerted hepatoprotective effects, optimizing glycemic control, regulating lipids, reducing uric acid, and alleviating hepatic fibrosis. This supports the clinical potential of dorzagliatin for T2D patients with MASLD.2.Dorzagliatin + Chiglitazar (Pan-PPAR Agonist): The combination of dorzagliatin and the pan-PPAR agonist chiglitazar demonstrates significant synergistic metabolic benefits in DIO mice model of MASLD. The glucose-lowering effect is superior to monotherapy. At the same time, it optimizes basal glucose metabolism and improves glucose disposal following glucose challenge. Compared with monotherapy, this combination regimen more effectively improves glucose tolerance, reduces insulin resistance, enhances insulin sensitivity and β-cell function, and elevates high-density lipoprotein cholesterol levels in mice. These findings underscore the potential of this combination to address metabolic dysregulation in MASLD and provide important preclinical support for subsequent clinical research to explore its therapeutic value in the metabolic and liver diseases.Together, these studies demonstrate that dorzagliatin’s core mechanism of restoring metabolic homeostasis operates synergistically with multiple targeted agents, supporting its therapeutic potential in obesity, MASLD, and other metabolic disorders.II. Large-Scale Post-Marketing Real-World Study (BLOOM) Validates Long-Term Efficacy and SafetyAt ADA 2026, Hua Medicine presented further key results from the BLOOM study, a large-scale post-marketing real-world investigation of dorzagliatin in routine clinical settings.BLOOM aims to evaluate the long-term safety and effectiveness of dorzagliatin in a broad, clinically diverse population of people with Type 2 diabetes. The BLOOM study enrolled 2,024 patients with Type 2 diabetes across 80 clinical centers in China (62% male; mean age 55.5 years; mean BMI 25.1 kg/m²; mean diabetes duration 7.9 years; baseline HbA1c 7.8%) with dorzagliatin treatment and follow-up lasting up to 52 weeks. It evaluated long-term safety and effectiveness of dorzagliatin as monotherapy or in combination with other anti-diabetic agents in real clinical settings, including elderly patients, people with renal impairment, and those on complex multiple-drug regimens including insulin. The study results demonstrated that:During the 52-week treatment period, no drug-related serious adverse events (SAEs) or severe hypoglycemia were reported over 52 weeks. Clinically meaningful hypoglycemia remained

KOSICE, SLOVAKIA, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - The original film by Vlado Zelezňák Jr. has achieved remarkable international success. The new Slovak-Japanese animated sci-fi film Angel & Meow celebrated its World Premiere by winning the prestigious Crystal Pine Award. The film proved its quality against an immense global competition of nearly 1,000 entries from 81 countries. This achievement is particularly notable as the film was produced as a fully independent project by the Slovak company GONG Art Company, led by Vlado Zelezňák Sr.The success took place at the 14th International Sound & Film Music Festival (ISFMF) in Varazdin, Croatia, which ranks among the world’s three most significant festivals dedicated to film music and sound. The gala ceremony was held in the magnificent historic setting of the Croatian National Theatre (HNK Varazdin).In the Company of Oscar Winners and Hollywood Stars The winners were selected by a prestigious international jury consisting of elite professionals—recipients and nominees of Oscar, Emmy, BAFTA, Grammy, and César awards. The jury president for this year was the legendary and respected actor Ciarán Hinds. Widely considered one of the most acclaimed actors of his generation, Hinds is known to audiences for global blockbusters such as Game of Thrones, Harry Potter and the Deathly Hallows, the Oscar-winning drama Belfast, and the animated phenomenon Frozen.Slovak creators stood on stage alongside the world’s absolute elite. Other award-winning personalities at this year’s festival included Hollywood actor Simon Pegg (Mission: Impossible, Star Trek), who received a Lifetime Achievement Award, and Oscar-winning sound designer James Mather (Top Gun: Maverick). The Slovak team shared the spotlight with elite sound professionals from the film Sirât, including Yasmina Praderas (Goya winner and Oscar nominee) and Laia Casanovas (European Film Award and Goya winner).Personal Moments from the Festival Stage The heart and engine of the project is Slovak producer, screenwriter, composer, and sound designer Vlado Zelezňák Jr., who accepted the award directly from the festival directors. During the gala, he experienced unforgettable personal encounters with the world’s biggest film stars."When we stood on stage after the announcement, I expressed my appreciation to the jury president, Ciarán Hinds, for his work. I was delighted that he already recognized our film—he responded immediately with a wide smile by singing the title of our project. It was a pleasant and spontaneous experience," recalls Vlado Zelezňák Jr.The meeting with Hollywood actor Simon Pegg was equally emotional. "I spoke with Simon on the day of the World Premiere, where I had the opportunity to introduce our film to him personally. When we met again on stage the next day during the awards ceremony, it was great to see that he was familiar with Angel & Meowand congratulated me with a smile again. These moments are a huge encouragement for my future work," adds the Slovak creator.The entire event was managed by the festival founders. The gala was hosted by Artistic Director Ozren K. Glaser, who publicly congratulated Vlado Zelezňák Jr. on stage, while Executive Director Marijana Glaser ceremoniously presented the Crystal Pine Award. "Our huge thanks go to the three main organizers from the Glaser family—Marijana, Ozren, and producer Zeljko Glaser. I would like to express my appreciation for their excellent, professional organization and for building a festival of a truly Hollywood standard, where one felt like they were at the Oscars from the very first moment," concludes Vlado Zelezňák Jr.A World Premiere of Visual Poetry Before an Elite Audience The World Premiere of Angel & Meow, held on May 22 at CineStar Varazdin, played to a fully packed theater. The audience consisted of an elite group of nominated composers, sound designers, and filmmakers from around the world. The premiere was attended in person by living legends of the film industry, such as Oscar-winning sound mixer Mark Ulano (Titanic, Inglourious Basterds), as well as singer and producer Kathy Kelly from the legendary group The Kelly Family.In addition to high-quality animation and visuals, the international jury praised the film’s powerful sound design, original score, and the overall story, all created by Vlado Zelezňák Jr. The visual and animation components were crafted by a top-tier Japanese team in Tokyo, led by director and lead animator Clemhyn Escosora from Adarnia studio (a subsidiary of Fuji Corp.).Global Sound Design and a Soundtrack as a Narrator Since the story relies on the pure power of image and sound, the meticulously designed sound and film music step into the spotlight, taking on the role of the primary narrator alongside the animation. The resulting soundtrack is exceptionally rich, varied, and intense."The sound design was created all over the world. While atmospheric sounds were recorded directly on the streets and coast of Cannes, the orchestral and electronic music was composed in studios in Slovakia. To achieve absolute authenticity, we recorded live animals and constantly experimented with sound," explains Vlado Zelezňák Jr. Over the 15-minute runtime, the viewer experiences diverse musical landscapes—from massive orchestral passages and intimate piano and guitar moments to pure sci-fi sounds of analog Moog synthesizers and wind instruments.Sound in the Hands of a Living Legend The final sound mastering was handled in the USA by an absolute legend in the field—Vlado Meller, in his prestigious American studio. Throughout his rich career, he has collaborated with icons such as Céline Dion, Andrea Bocelli, and the Red Hot Chili Peppers. Meller recently exclusively finished Dolby Atmos mastering for Michael Jackson’s legendary albums for Sony USA, released in conjunction with the recently unveiled biographical film hit Michael.Angel & Meow has shown from the very start that independent Slovak production from the GONG Art Company workshop, combined with an original script, film music, and sound design, can successfully stand its ground on the international stage against the world's biggest productions.About GONG Art Company30 Years of Creativity and Innovation GONG Art Company is an established pillar of the Slovak audiovisual scene with a nearly 30-year history. The company is renowned for its long-standing technological and creative co-production work with Slovak National Television and Radio, providing comprehensive music production for iconic projects such as Hviezdička and Zlatá brána. The company has been awarded multiple Gold and Platinum records for its music production and children's audio titles.Today, GONG operates as a modern production house focused on international film co-productions. The company manages its own film projects, with in-house recording studios dedicated to film scoring and sound design. This infrastructure allows for simultaneous production across multiple works—while the soundtrack for Angel & Meow was being composed in one studio, another was handling sound post-production for the documentary Man from the Mountain, which is also heading to international film festivals this year.GONG is also the founder of the global platform FMC (Film Music Contest & Festival), which connects elites from Hollywood and Netflix with global talent. The team regularly participates in key industry markets such as Cannes (Marché du Film), Annecy (MIFA), and Berlinale (EFM), building on a tradition of high-quality original work with the ambition to succeed in the global market.More information: www.angelandmeow.com Media Contact: Mgr. Vlado Zelezňák JR. Phone: +421 911 789 888 Email: press@angelandmeow.com Facebook: https://www.facebook.com/angelandmeowmovie/ Instagram: https://www.instagram.com/angelandmeowmovie/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative.These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities.Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swarming autonomy detection capability."Blue Magic Netherlands is our window into the Dutch innovation ecosystem," said Brad Lunn, Managing Director, GA‑ASI. "We are not just scouting ideas. We are deploying capital, engineering resources, and access to platforms to help these companies scale. We're making these new investments because it is clear to us that the Netherlands is one of the most dynamic technology hubs in Europe."The six new GA‑ASI portfolio companies are:OPT/NET B.V. - GA-ASI, alongside its GA-Intelligence affiliate, will be working with OPT/NET to explore collaboration opportunities for a variety of AI-related missions, including drone swarm management and dark vessel detection.Vaeridion B.V. - GA-ASI will be working with Vaeridion to evaluate their advanced battery pack technology for use in current and future GA-ASI platforms.Touchwaves B.V. - GA-ASI will be evaluating Touchwaves' haptic technology for use in remotely piloted UAS environments to determine the potential benefits to long-duration missions and aircrew information overload.FDCL Defence B.V. - GA-ASI and GA-Intelligence will be working with Fiducial to explore the effectiveness of the company's technology toward massively scaled low-cost future platforms.Vydar Commercial B.V. - GA-ASI will evaluate Vydar's technology in a variety of relevant GPS-denied environments and GA-ASI and GA-EMS platforms.Emproof B.V. - GA-ASI will evaluate the effectiveness of Emproof's data protection technology for applicability to current and future GA-ASI platforms.GA‑ASI expects to announce additional investments from the 2025 BMN cohort in the coming months, as technical evaluations and co‑development discussions progress.About Blue Magic VenturesBlue Magic Ventures is GA‑ASI's corporate venturing initiative, designed to identify, invest in, and scale breakthrough technologies from startups and innovators around the world. Through capital investment, access to platforms, and deep technical collaboration, Blue Magic Ventures accelerates the path from concept to capability for dual‑use technologies.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HO CHI MINH / SEOUL, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Global content-tech company TON Corporation (CEO Henry Kim) today announced that it will officially launch 'TonTV', its Telegram-native short-drama platform, worldwide in September 2026. TonTV lets the ~1 billion people who use Telegram each month instantly and freely watch short dramas with a single Telegram account — with no separate app install and no complicated sign-up.Short drama is one of entertainment's fastest-rising categoriesShort-form drama has moved to the center of global media consumption. Global in-app revenue for short dramas reached $2.98 billion in 2025, up 115% year over year, and in Q4 2025 short-form titles overtook long-form streaming apps in downloads for the first time (733M vs. 658M), according to Sensor Tower and Omdia. With short runtimes, high completion rates, and mobile-first immersion, the format is growing fastest among younger viewers. TonTV places dramas of around two minutes at the heart of this trend — short but intense chapters that build a "can't-stop-once-you-start" experience.The Telegram Mini App: tearing down the barrier to entryTonTV's core strength is that it runs atop Telegram, a massive global platform. Existing OTT services require a long entry sequence — app-store search → download → install → sign-up → enter payment details. TonTV removes it: open the Mini App inside Telegram → watch instantly, for free.The user reach that global OTT leaders such as Netflix and Disney+ built over years and at enormous cost is something TonTV can address from day one, across Telegram's ~1 billion monthly users. This dramatically lowers user-acquisition cost while driving early growth through natural word-of-mouth across Telegram's groups and channels.Three years of preparation, and "why we can win"TonTV did not appear overnight. Over the past three years, TON Corporation has focused on platform-technology development, global content partnerships, and a local-operations model in preparation for launch.CTO Tony cited the following reasons TonTV can be a market "game changer" rather than a late follower:Frictionless reach — among the first specialized short-drama platforms to reach Telegram's ~1 billion monthly users, free, in one clickFree entry — anyone can start at no cost, a strong advantage for early user acquisitionNetwork effects — discussion, sharing, and recommendation happen at the same moment as viewingViewer-participation rewards — enjoying content itself returns benefits and rewards, building loyaltySimultaneous global release — worldwide at once, with no region-by-region app-store approvalOn these strengths, TonTV aims to grow beyond short drama into real-time formats such as live streaming over time.A 'new stage' for producers, actors, and staff worldwideTonTV goes beyond a viewing platform to open opportunity for the global content industry. Producers can showcase work directly to a global audience; actors and staff can widen their stage across borders. For emerging teams and new actors who have struggled to get a chance at traditional broadcasters or large OTTs, TonTV offers an open stage judged on ability — creating jobs across planning, production, acting, and post-production."Global one platform, local content"TonTV places local subsidiaries in major markets — Korea, Japan, Vietnam, India, Indonesia, and the Philippines — planning and producing content suited to each region's culture on the ground. Combining a global platform's scale with local content's intimacy, TonTV aims to be a true global OTT where anyone can enjoy "stories from home." The local-subsidiary model expands content and markets quickly while keeping head-office cost low.A dual revenue model: "growth and profit together"TonTV operates a dual model: a free, ad-supported tier where all users watch at no cost, and a premium subscription for an ad-free experience. Advertiser acquisition and content production through local subsidiaries create a cycle in which ad and subscription revenue grow with the user base. Telegram's low acquisition cost and short-form's high completion rates support this model.Comment from TON Corporation CTO TonyCTO Tony said: "For the past three years we've focused everything on creating the easiest, most enjoyable way to watch drama. On Telegram — a playground of a billion people — TonTV sets a new standard for short drama anyone can enjoy free, with a single account."He added: "TonTV will create the best experience for viewers, a new stage for creators, and new jobs for the industry — and our ambition is to become the global leader in short-drama and live content."Future plansFrom its September 2026 launch, TonTV plans to rapidly expand its content lineup and service regions, broaden from short drama into real-time formats such as live streaming, and accelerate global expansion through its local subsidiaries.About TON CorporationTON Corporation is a global content-tech company headquartered in Ho Chi Minh, Vietnam. Through TonTV, its Telegram-native short-drama platform, it aims to deliver a new entertainment experience to users worldwide and open opportunity for global content creators.Media ContactBrand: TON CorporationContact: PR TeamWebsite: https://tontv.toncorp.ioTelegram: https://t.me/TontvOfficialChannel Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008"), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world's largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical studyPresentation Number: 3079-LBPresentation format: PosterDate/Time: June 7, 2026 01:30 PM - 02:30 PM (Local Time)Location: Hall D-EResults:In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community's interest in the scientific value and clinical potential of CMS-D008 in the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. Studies have shown that aceclidine's mechanism of action (MOA) is well positioned to create a pinhole pupil effect while avoiding the impairment of distance vision called myopic shift. Aceclidine's unique pupil selective MOA, in which miosis is decoupled from myopic shift, is expected to allow it to target a broad patient population.According to publicly available information, LNZ100 received approval in the United States in July 2025 and was commercially launched in October of the same year. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. The therapy has the potential to address a significant unmet medical need in China and position itself as a best-in-class, non-invasive treatment option for presbyopia.“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”Ms. Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL, said: “We are confident that Everest Medicines’ strong commercialization capabilities will accelerate LNZ100’s market access and bring this innovative treatment to more presbyopia patients in China. Following this transaction, CORXEL’s pipeline will be entirely focused on cardiometabolic therapies. The proceeds from the transaction will enable CORXEL to accelerate the global clinical development of its innovative cardiometabolic pipeline.”Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye’s adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100 percent at the age of 52 in China. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible and invasive operation, has very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved.The NDA acceptance of LNZ100 by the National Medical Products Administration (NMPA) of the People’s Republic of China is based on the data from China Phase 3 Trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 6-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. The trial has enrolled 300 participants.The results showed that LNZ100 achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). Results also showed (all p

OTTAWA, ON, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec.The Study was completed by WSP Canada Inc. ("WSP"), one of the world's leading engineering and environmental consulting firms, under the supervision and management of IOS Geosciences Inc. ("IOS"), as part of the environmental studies supporting the advancement of Lac Knife toward future permitting and development.The AQA evaluated emissions associated with the proposed open pit mine, processing facility, tailings storage facility, stockpiles, haul roads, crushing operations, and supporting infrastructure under conservative maximum operating scenarios. Atmospheric dispersion modelling using Aeromod software, was completed in accordance with the requirements of Quebec's Reglement sur l'assainissement de l'atmosphere ("RAA") and applicable guidance from the Ministere de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs ("MELCCFP").According to WSP's conclusions, the modelling results demonstrate that predicted contaminant concentrations remain in compliance with applicable Quebec ambient air quality standards and criteria under the assessed operating conditions. WSP further concluded that all evaluated contaminants met applicable regulatory thresholds. The Study also noted that prevailing winds are predominantly directed toward the south-southeast, away from nearby public infrastructure, residences, and seasonal fishing cabins."Environmental permitting is one of the most important value-creation stages in the development of any critical mineral project," said Dean Hanisch, CEO of Focus Graphite. "The completion of the Air Quality Assessment represents another key component of the broader environmental review process and brings us closer to completing the environmental studies required to support future permitting activities. As these workstreams are completed, Lac Knife continues to become increasingly de-risked from both a technical and environmental perspective while strengthening its position as a strategic North American graphite asset."The Study evaluated a broad range of potential emissions, including particulate matter, nitrogen oxides, sulphur dioxide, carbon monoxide, crystalline silica, and various metals, using a detailed atmospheric dispersion model of the Project area and surrounding receptors based on five years of regional meteorological data.Advancing Toward Environmental Assessment CompletionThe AQA forms part of the broader environmental and permitting work program being advanced at Lac Knife and represents another important milestone toward completion of the environmental and social impact assessment ("ESIA") process. With this Study now complete, the Company is advancing the remaining key environmental workstreams, including the hydrogeological assessment and dam breach analysis, which are expected to further support permitting activities and future project development.The completion of the AQA builds on a series of technical, environmental and infrastructure achievements that continue to de-risk the Project and strengthen Lac Knife's position as a strategically important North American graphite asset. As demand for secure and reliable graphite supply continues to grow, Focus remains focused on advancing the Project through the key milestones required for future development.Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals — reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc., please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the advancement of the Lac Knife Graphite Project toward permitting readiness and future development; the completion and timing of the remaining environmental studies required to support the environmental and social impact assessment ("ESIA") process, including the hydrogeological assessment and dam breach analysis; the anticipated completion of environmental baseline, technical and permitting workstreams; the Company's ability to obtain required permits, approvals and authorizations; the anticipated benefits of completed environmental and technical studies, including the Air Quality Assessment; the timing and completion of future project milestones; the future development, construction and operation of the Lac Knife Project; the role of the Project in supporting North American and allied critical mineral supply chains; and the Company's long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300471 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1. Sustainable & Climate TechnologyAlbacastor Technology Limited2. AIGreen Limited 3. Asgard Group Limited 4. Formwork IO5. Green Vigor Limited6. Laputa Eco-Construction Material Company Limited7. LeafIoT Technology Limited8. Plasticvore Chain Ltd 9. AI and Software Solutions Cogniser Infotech Ltd10. D-Engraver Limited11. Midas Analytics Limited 12. OxGen Holdings Limited13. Pantheon Lab Limited14. SagaDigits Limited15. Robotics and Microelectronics TechnologyAnlaseo Technology Limited16. Bacbudy Limited17. Cybercrystal Technology Co., Limited18. Harmony SkyTech Limited19. Oriental Materials Hong Kong Limited20. Robocore Technology Limited21. Health TechnologyEieling Technology Limited22. Hong Kong Bionic Beet Robotics Limited23. Point Fit Technology Limited 24. UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion. During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IRVINE, CA, June 7, 2026 - (ACN Newswire via SeaPRwire.com) - iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings a range of promotional offers and localized services to customers in Hong Kong and Southeast Asia, reflecting the company’s ongoing commitment to enhancing accessibility and customer experience across international markets.Founded in 1996, iHerb has expanded its operations to 185 countries and regions and now serves more than 11 million active users worldwide. Through its direct sourcing model and global fulfillment network, the company has focused on providing consumers with access to a broad range of international health, wellness, beauty, and personal care products.Unlike traditional cross-border retail models that often involve multiple intermediaries, iHerb purchases products directly from manufacturers and distributes them through its own warehouse network. The company stated that this approach helps improve supply chain transparency and product traceability while streamlining international delivery.As part of the 618 campaign, iHerb highlighted a selection of products from popular categories frequently purchased by consumers, including dietary supplements, personal care products, sports nutrition items, and beauty products.Among the featured products are:California Gold Nutrition LactoBif(R) 30 Billion Probiotics (CGN00965), a probiotic supplement packaged in individually sealed blister packs for convenient storage and transportation.Doctor's Best High Absorption Magnesium (DRB00087), a magnesium supplement formulated using Albion(R) TRAACS(R) chelation technology.Nature's Way Alive! Hair, Skin and Nails Gummies (NWY11534), a strawberry-flavored gummy supplement containing vitamins, collagen, and other nutritional ingredients.Metagenics OmegaGenics(R) Fish Oil EPA-DHA (MTG93873), a fish oil supplement containing EPA, DHA, and omega-3 fatty acids.ProHealth Longevity NMN Pro 1000 (PHV77904), an NMN supplement designed for adult consumers interested in wellness-focused nutritional products.The company noted that these products represent some of the diverse categories available on the platform, which currently offers nearly 3,000 brands and more than 50,000 products globally.To commemorate its 29th anniversary and the 618 Shopping Festival, iHerb announced several promotional initiatives for customers in Hong Kong and Southeast Asia:New customers can use the code WELCOME7 to receive a first-order discount.From June 11 to June 20, customers can use 618SALE26 for sitewide promotional savings.Additional regional promotions are available through the end of June using code 6HK75, subject to applicable terms and conditions.Customers in Hong Kong may qualify for free shipping on eligible orders and access local express delivery options.In addition to promotional activities, iHerb continues to expand localized services across Asian markets. Customers can shop through the company's website and mobile application, with support for local currencies and multiple payment methods, including credit cards and digital wallets.As iHerb marks its 29th anniversary, the company stated that it will continue investing in supply chain infrastructure, customer service, and regional fulfillment capabilities to support consumers seeking access to international health and wellness products.Company: iHerb, LLCContact Person: Kelly ChaiEmail: china.sm@iherb.com Website: iherb.com Telephone: (1) 951 6163600 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tashkent, Uzbekistan, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), completed its first stop in Kazakhstan from 1 to 3 June and are now visiting Tashkent, the capital of Uzbekistan, for the final leg of its Central Asia tour from 4 to 5 June. During the visit, the delegation met with senior representatives of the local government and business communities, successfully advancing collaboration opportunities across multiple sectors.The HKTDC will follow up on key projects facilitated during the visit by providing professional post-‘mission business matching and support services, with a view to expediting project implementation while continuing to assist Hong Kong enterprises in exploring further international cooperation opportunities.The business delegation facilitated the signing of 66 memoranda of understanding (MoUs) and agreements during its visit to Kazakhstan and Uzbekistan, covering areas such as trade, investment, finance, technology and aviation. In addition, 15 cooperation agreements were signed at the government level, while non-delegation members signed 15 MoUs in areas including academia and culture, bringing the total number of agreements and MoUs signed to 96. These outcomes have laid a solid foundation for deepening economic and trade ties among Hong Kong, the Chinese Mainland, Kazakhstan and Uzbekistan, underscoring Hong Kong’s role as a key platform for Mainland enterprises to go global and further promoting long-term collaboration with Central Asian markets. Looking ahead, the parties look forward to welcoming more Central Asian enterprises to Hong Kong and HKTDC’s flagship international conferences and exhibitions, including the Belt and Road Summit and InnoEX, to capitalise on Hong Kong’s strengths as an international business and trading hub and further deepen cooperation.During its stay in Uzbekistan, the delegation met with senior officials, trade bodies and business representatives, including the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan and Uzbekistan Chamber of Commerce, and IT Park Uzbekistan, to gain in-depth insights into the country’s economic developments, market environment and investment opportunities.Summing up the Central Asia visit, Mr Lee said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Mr Lee held meetings with the Presidents, Prime Ministers and other senior officials of the two countries. Both sides agreed to strengthen high-level communication and pursue multi-faceted collaboration. The Government of Uzbekistan has agreed to establish a Consulate General in Hong Kong. In addition, multiple agreements were signed, including projects with substantial investment value.Both sides recognised that the hub-to-hub cooperation model will create broader and deeper collaboration between the two regions and drive high-quality development. They will increase high-level mutual visits, support each other’s promotional activities and jointly expand their networks.”To deepen economic and trade cooperation, the HKSAR Government and the HKTDC jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officials. Prof Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”The delegation comprised business leaders from Hong Kong and 17 provinces and municipalities across the Chinese Mainland, spanning a broad range of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries as well as the media. For the first time, representatives from journalism associations joined the delegation, in response to the Policy Address’s initiative to assist the local media in expanding their network beyond Hong Kong and telling the good stories of Hong Kong. During its Kazakhstan visit, the delegation facilitated 43 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority Hong Kong and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte China and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLP29.Goldford Group and Gas Energy Solution LLP30.Hong Kong News Executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC31.Jardine Matheson and KIDF32.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan33.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology34.PCCW Limited and Kazakhtelecom35.PCCW Limited and Khabar Agency JSC36.SCMP and Astana International Financial Centre (AIFC)37.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub38.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan39.Standard Chartered Bank and Development Bank of Kazakhstan40.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.41.Templewater Limited and Freedom Holdings42.The Standard and Freedom Horizons43.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC During its Uzbekistan visit, the delegation facilitated 23 MoUs and agreements, including:1.Hong Kong Trade Development Council (HKTDC) and Chamber of Commerce and Industry of Uzbekistan (CCIU)2.Hong Kong Trade Development Council (HKTDC) and IT Park Uzbekistan3.Airport Authority Hong Kong and Fly Khiva Group4.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and SINOCHEM PLASTICS GROUP “MCHJ XK”5.Belt and Road General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)6.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP7.Chinese Manufacturers' Association of Hong Kong and Chamber of Commerce and Industry of Uzbekistan (CCIU)8.Federation of Hong Kong Industries (FHKI) and Tashkent City Municipality9.Cyberport and IT Park Uzbekistan10.The Hong Kong General Chamber of Commerce and Chamber of Commerce and Industry of Uzbekistan (CCIU)11.Law Society of Hong Kong and Chamber of Advocates of the Republic of Uzbekistan12.A-Grade Energy Ltd and Zarafshan Golden Group of Uzbekistan13.China International Capital Corporation Limited and National Bank of Uzbekistan14.China International Capital Corporation Limited and Tashkent City Municipality of the Republic of Uzbekistan15.Deloitte China and Orient Group and CITIC16.Goldford Group and Automated Solutions Center17.Templewater Limited and Uzbek-Oman Investment Company LLC18.Templewater Limited and CSCEC INTERNATIONAL MCHJXK (China State Construction International Holdings Limited)19.Templewater Limited and Tashkent City Municipality of the Republic of Uzbekistan20.The Standard and Tashkent City Municipality of the Republic of Uzbekistan21.Changchun GeneScience Pharmaceutical Co., Ltd. with Vita Group Farm22.Guangzhou Pharmaceutical Holdings Limited and ADN Pharm-Sanoat Uzbekistan23.Shaanxi Tirain Science & Technology Co., Ltd. and Geodesy, Cartography and Remote Sensing Department, Cadastral Agency under the State Tax Committee of the Republic of UzbekistanOther non-delegate organisations have also taken this opportunity to establish collaborations in various fields, including education, culture, and more:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan5.City University of Hong Kong and Satbayev University6.City University of Hong Kong and Tashkent State Technical University7.Education University of Hong Kong and Nazarbayev University8.HKT and Education University of Hong Kong9.Hong Kong Polytechnic University and Nazarbayev University10.Hong Kong Polytechnic University and El-Yurt Umidi Foundation11.Hong Kong Polytechnic University and New Uzbekistan University (NUU)12.Thei and BILIM-INNOVATION International Social Foundation13.Thei and L.N. Gumilyov Eurasian National University14.CCBI and Uzbekistan BA Association15.West Kowloon Cultural District Authority – Hong Kong Palace Museum and State Museum of History of UzbekistanPhoto download: https://bit.ly/4fmUpRLSumming up the Central Asia visit, John Lee, Chief Executive of the HKSAR, said: “The purpose of this visit is threefold. First, to further explore emerging markets and lay a solid foundation for long-term economic and trade development. Second, to strengthen government-to-government relations and promote closer bilateral cooperation. Third, to establish a hub-to-hub cooperation model.During the visit, I led a delegation of 75 business leaders from Hong Kong and Mainland enterprises to Kazakhstan and Uzbekistan — the two largest economies among the five Central Asian countries. The delegation attended more than 20 events and inspected multiple projects in the finance, innovation and technology, and infrastructure sectors. The visit was highly successful and achieved eight major outcomes.”Prof Frederick Ma, Chairman of the HKTDC, joined John Lee, Chief Executive of the HKSAR, senior officials of the HKSAR Government and members of the delegation in meeting the media, noting that the Central Asia visit led by the Chief Executive has successfully opened doors to business cooperation with Central AsiaThe HKSAR Government and the Hong Kong Trade Development Council (HKTDC) jointly hosted a business dinner in Uzbekistan, attracting around 230 business leaders and senior officialsProf Frederick Ma, Chairman of the HKTDC, said at the dinner: “The Central Asia visit has delivered fruitful outcomes and once again reaffirmed the trust placed by Central Asian countries in Hong Kong’s role as a bridge. In tapping emerging markets, such as Kazakhstan and Uzbekistan, Hong Kong, with its international credibility, robust institutional framework, world-class professional services and the HKTDC’s global network, serves not only as a key springboard for Mainland enterprises to go global, but also as a gateway for overseas enterprises to enter the Mainland market, effectively facilitating two-way investment and trade flows. This virtuous cycle of going global and attracting foreign investment fully demonstrates Hong Kong’s irreplaceable value under the Belt and Road Initiative as well as the HKTDC’s strengths as the preferred platform for enterprises pursuing two-way expansion.”During its visit to Uzbekistan, the delegation facilitated 23 memoranda of understanding (MoUs) and agreementsThe delegation met with representatives of the Ministry of Investment, Industry and Trade (MIIT) of Uzbekistan to gain in-depth insights into bilateral trade and investment opportunities. During the meeting, Prof Frederick Ma, Chairman of the HKTDC, met with Khodjayev Jamshid Abdukhakimovich, Deputy Prime Minister of the Republic of UzbekistanThe delegation met with representatives of the Uzbekistan Chamber of Commerce to gain in-depth insights into the country’s economic developments, market environment and investment opportunitiesThe delegation visited IT Park Uzbekistan to learn about the latest developments in innovation and technologyMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation marks an important milestone in the Group’s strategy to diversify its manufacturing footprint beyond the Chinese Mainland while deepening its production presence in Southeast Asia.The Penang facility spans approximately 60,000 square feet and houses 12 production lines, providing a monthly production capacity of 250,000 to 300,000 units. It operates as an OEM manufacturing base for industrial electronics, environmental control and electronics power modules, serving international customers. The additional capacity broadens the Group’s manufacturing scale, reflects growing customer demand and creates a platform for further business development.The opening builds on the Group’s strategic initiatives completed in 2025, including the acquisition of manufacturing operations in Penang, Malaysia, and Ho Chi Minh City, Vietnam. The move into Malaysia represented the Group’s first production foothold outside the Chinese Mainland. Following the acquisition in August 2025, the Group has expanded and upgraded the Penang facility with advanced equipment and process improvements to strengthen efficiency and quality control. It now manufactures irrigation sensors, thermostats, security devices and lithium battery packs.Mr. Lam Yin Kee, Chairman and Executive Director of Alltronics, said, “The Penang facility plays an important role in advancing the Group’s strategy to build a more diversified manufacturing network. Together with our expansion into Vietnam, we are reinforcing our production capabilities and increasing supply chain flexibility across our operations. These initiatives strengthen the Group’s resilience and agility in supporting our customers in an increasingly dynamic global environment.”Mr. Lam Chee Tai, Eric, Chief Executive and Executive Director of Alltronics, added, “The Penang operation is ramping up steadily and is already supporting a growing pipeline of orders from existing and new customers. With expanded production lines and upgraded systems, we are ready to scale output as demand increases. The Group is evaluating the potential establishment of another facility in Malaysia with comparable capacity to support the Group’s next phase of growth.” Official representatives of Malaysia, together with Alltronics’ Board of Directors and management, officiate at the ribbon-cutting ceremony for the Group’s new Malaysia facility. With 12 production lines and a monthly capacity of 250,000 to 300,000 units, Alltronics’ Malaysia facility broadens the Group’s manufacturing scale and supports growing customer demand.About Alltronics Holdings Limited (Stock code: 833)Alltronics Holdings Limited is mainly engaged in the design and manufacture of a wide range of electronic products with quality and style. The Company is a constituent stock of the Morgan Stanley Capital International (“MSCI”) Hong Kong Micro Cap Index. For more information, please visit the company website http://www.alltronics.com.hk/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GLASGOW / HONG KONG - Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m². Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics"This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases," said Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics. "We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide."About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. For more information, please visit www.hightidetx.com Contact: pr@hightidetx.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves. ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com